Implementation of a rapid genotypic assay to promote targeted ciprofloxacin therapy of neisseria gonorrhoeae in a large health system

Clinical Infectious Diseases

Volumn 64, Issue 9, 2017, Pages 1268-1270

  Allan Blitz, Lao Tzu ^a   Humphries, Romney M ^a   Hemarajata, Peera ^a   Bhatti, Ashima ^b   Pandori, Mark W ^c   Siedner, Mark J ^d   Klausner, Jeffrey D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Alameda County Public Health   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antibiotic resistance; Ciprofloxacin; GyrA; Neisseria gonorrhoeae

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING);

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ASSAY; FEMALE; GENE; GONORRHEA; GYRA GENE; HEALTH CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; RAPID GYRASE A GENOTYPIC ASSAY; REAL TIME POLYMERASE CHAIN REACTION; CLASSIFICATION; DRUG UTILIZATION; GENETICS; GENOTYPING TECHNIQUE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES;

ANTI-BACTERIAL AGENTS; CEFTRIAXONE; CIPROFLOXACIN; DNA GYRASE; DRUG UTILIZATION; FEMALE; GENOTYPING TECHNIQUES; GONORRHEA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE;

EID: 85020003605     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw864     Document Type: Article

References (13)

1. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev 2014; 27:587-613.
2. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T 2015; 40:277-83.
3. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta, GA: CDC, 2013.
4. Siedner MJ, Pandori M, Castro L, et al. Real-time PCR assay for detection of quinolone-resistant Neisseria gonorrhoeae in urine samples. J Clin Microbiol 2007; 45:1250-4.
5. Allan-Blitz L, Klausner JD. Neisseria gonorrhoeae susceptibility to ciprofloxacin. MLO Med Lab Obs 2016; 48:30.
6. Kirkcaldy RD, Harvey A, Papp JR, et al. Neisseria gonorrhoeae antimicrobial susceptibility surveillance - the Gonococcal Isolate Surveillance Project, 27 sites, United States, 2014. MMWR Surveill Summ 2016; 65:1-19.
7. Buono SA, Watson TD, Borenstein LA, Klausner JD, Pandori MW, Godwin HA. Stemming the tide of drug-resistant Neisseria gonorrhoeae: the need for an individualized approach to treatment. J Antimicrob Chemother 2015; 70: 374-81.
8. Hemarajata P, Yang S, Soge OO, Humphries RM, Klausner JD. Performance and verification of a real-time PCR assay targeting the gyrA gene for prediction of ciprofloxacin resistance in Neisseria gonorrhoeae. J Clin Microbiol 2016; 54:805-8.
9. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995; 20(suppl 1):S47-65.
10. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012; 7:1401-22.
11. Banerjee R, Teng CB, Cunningham SA, et al. Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing. Clin Infect Dis 2015; 61:1071-80.
12. Echols RM, Heyd A, O'Keeffe BJ, Schacht P. Single-dose ciprofloxacin for the treatment of uncomplicated gonorrhea: a worldwide summary. Sex Transm Dis 1994; 21:345-52.
13. Klausner JD. Clinical validation of a molecular test for ciprofloxacin-susceptibility in Neisseria gonorrhoeae. Bethesda, MD: National Library of Medicine. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02961751). Accessed 23 November 2016.